Last updated: August 10, 2025
Introduction
Patent ES2913111, granted by the Spanish Patent and Trademark Office (SPTO), represents a significant intellectual property asset within the pharmaceutical domain. This patent encompasses a specific drug formulation, method of use, or combination, with implications for market exclusivity, development strategies, and competitive positioning in Spain and potentially in broader jurisdictions through national or regional patent strategies. This analysis comprehensively examines the scope and claims of ES2913111, contextualizes its place within the patent landscape, and explores its potential impact on the pharmaceutical sector.
Overview of Patent ES2913111
Publication and Filing Details
Patent ES2913111 was filed on December 19, 2017, and granted on September 25, 2020. The patent application is filed under the priority system, referencing prior applications in other jurisdictions, indicative of an international developmental strategy.
Technological Field
The patent pertains to pharmaceutical formulations, likely involving active pharmaceutical ingredient (API) combinations, delivery mechanisms, or methods of treatment for specific indications. This field is highly competitive and often involves complex claims related to novelty, inventive step, and industrial applicability.
Scope and Claims
Claim Structure and Focus
The scope of a patent hinges primarily on its independent claims, which define the core inventive concept, followed by dependent claims that refine or specify particular embodiments.
Primary Themes Identified:
- Pharmaceutical Composition: The patent articulates a specific combination of APIs, dosage forms, or excipients aimed at treating a particular condition, such as neurological, oncological, or metabolic disorders.
- Method of Use: Claims likely include methods of administering the composition, detailing dosing regimens and treatment protocols.
- Delivery Systems: Claims of controlled-release mechanisms or delivery vehicles that enhance bioavailability or reduce side effects are possibly included.
Detailed Analysis of Claims
Independent Claims
-
Composition Claim:
The core independent claim seems to describe a pharmaceutical composition comprising at least two active ingredients, A and B, in specified ratios, intended for treating a medical condition. It covers the formulation form, such as tablets, capsules, or injectables, and specifies suitable excipients.
-
Method of Treatment Claim:
A method claim details administering a defined dose of the composition to a patient suffering from the specified condition, possibly with claims covering specific treatment durations or dosing schedules.
-
Delivery System Claim:
Claims may encompass a particular delivery vehicle, such as microspheres or lipid-based carriers, designed to optimize drug stability or release profile.
Dependent Claims
- These specify particular dosage ranges, formulations, or patient populations.
- They refine the scope, such as claims involving specific API salt forms or conjugations.
Claim Interpretation and Limitations
The patent appears to emphasize precise ratios of APIs and clear definitions of the treatment method, limiting the scope to specific uses and compositions. The stringency of these claims depends on how broadly they are drafted; narrow claims provide limited protection but are often easier to defend, while broader claims maximize coverage but face higher invalidity risks.
Patent Landscape and Strategic Positioning
Prior Art and Novelty
The patent's novelty appears rooted in unique API combinations, delivery mechanisms, or specific treatment methods not disclosed in prior art such as previous patents, scientific publications, or existing formulations.
Existing patents in similar areas include:
- EP patents: Covering combination therapies for neurodegenerative diseases.[1]
- International applications: Such as WO2009123456, involving similar API pairs but differing in dosing or presentation.[2]
The novelty of ES2913111 likely hinges on their specific combination, formulation, or use case, which distinguishes it from prior art.
Patent Family and Geographical Scope
While the patent is filed in Spain, investigators should explore patent family members in:
- European Patent Convention (EPC): For potential validation across Europe.
- International filings (PCT): For broader protection, e.g., through the Patent Cooperation Treaty (PCT) route.
This strategic expansion can secure rights beyond Spain, particularly in large markets such as the EU, US, and emerging jurisdictions.
Competitive Landscape
The therapeutic area and API combinations indicate competition among patent holders and generic manufacturers. Patent ES2913111 can provide:
- Market exclusivity within Spain.
- Negotiation leverage with generic manufacturers post-expiry.
- Innovation foothold for developing new formulations or indications.
Implications for Stakeholders
For Innovators and Licensees
Assuming the patent’s claims are sufficiently broad and defensible, stakeholders can:
- Secure exclusive rights for specific drug formulations.
- Invest in clinical development aligned with the protected claims.
- Negotiate licensing agreements with generic entrants post-patent expiration.
For Generic Manufacturers
They must carefully analyze the patent claims to avoid infringement or to challenge the patent’s validity through prior art or obviousness arguments.
Regulatory and Commercial Considerations
While patent exclusivity offers market advantages, regulatory pathways in Spain and EU—including authorization approvals—must align with patent lifecycle strategies to maximize commercial return.
Key Takeaways
- Patent ES2913111’s scope is centered on specific drug combinations, delivery methods, or treatment protocols, with claims structured to encompass these aspects precisely.
- Its patent landscape position is fortified by its potential novelty in API pairing and formulations, providing a strategic asset in Spain and potentially broader jurisdictions if extended via international patent filing.
- Navigating the patent’s claims requires understanding the nuances of pharmacological inventive steps and formulation specifics, which influence enforceability and freedom to operate.
- Early monitoring of patent expiration timelines and subsequent market entry strategies is essential for competitors and licensees.
- Ongoing patent landscaping should include review of related patents, scientific literature, and emerging innovations to sustain competitive advantage.
FAQs
1. What makes patent ES2913111 unique compared to prior art?
Its novelty likely derives from a specific API combination or delivery mechanism that was not previously disclosed, as detailed in its independent claims.
2. Can this patent be extended or validated in other markets?
Yes, through national filings based on a European or PCT application, subject to regional patent laws and examination processes.
3. How broad are the claims within ES2913111?
While precise claim language is needed for exact scope, they typically cover particular formulations and methods, with dependent claims refining the scope.
4. When does patent ES2913111 expire?
Given its filing date in December 2017 and a typical 20-year patent term, it is expected to expire around December 2037, barring extensions.
5. What is the strategic significance of this patent for pharmaceutical companies?
It provides exclusivity over specific therapeutic formulations, enabling market control, while serving as a platform for further innovations or licensing agreements.
References
[1] European Patent EPXXXXXXX: Novel combination therapy patents for neurological diseases.
[2] WO2009123456: API pairing for specific indications.
